Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezabenlimab and Brigimadlin in TLS-Positive Solid Tumors
NCT06084689Phase 2Withdrawn
- Sponsor
- Institut Bergonié
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of brigimadlin, ezabenlimab in soft tissue sarcoma (STS), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), biliary tract cancer (BTC), sponsored by Institut Bergonié. Planned start Jun 2024; status: withdrawn.
02
Drugs
brigimadlinezabenlimab
03
Conditions
soft tissue sarcoma (STS)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)colorectal cancer (CRC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06084689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084689.